Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Melanoma Institute Australia
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
57High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06999980CT.gov Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation) | — | Recruiting | — | — | — |
NCT07410676CT.gov EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07287917CT.gov Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07349303CT.gov Neoadjuvant Pembrolizumab in Patients With Stage IIb/c Melanoma | — | Recruiting | — | — | — |
NCT07130032CT.gov Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade | — | Recruiting | — | — | — |
NCT06624644CT.gov A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | — | Recruiting | — | — | — |
NCT06984328CT.gov Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) | — | Terminated | — | — | — |
NCT07448831CT.gov A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma. | — | Recruiting | — | — | — |
NCT06743126CT.gov SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | — | Recruiting | — | — | — |
NCT06771544CT.gov Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma | — | Recruiting | — | — | — |
Show 56 more trialsShow fewer
NCT06784648CT.gov Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT06545682CT.gov Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) | — | Recruiting | — | — | — |
NCT05970497CT.gov A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06320353CT.gov Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma | — | Unknown | — | — | — |
NCT05824975CT.gov A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | — | Recruiting | — | — | — |
NCT05764395CT.gov Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors | — | Active Not Recruiting | — | — | — |
NCT05669430CT.gov A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT06307093CT.gov Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms | — | Unknown | — | — | — |
NCT05492682CT.gov START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer | — | Recruiting | — | — | — |
NCT05576077CT.gov A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT05585034CT.gov Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors | — | Completed | — | — | — |
NCT05585320CT.gov A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05544929CT.gov A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | — | Active Not Recruiting | — | — | — |
NCT05341349CT.gov Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT05986331CT.gov Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma | — | Unknown | — | — | — |
NCT05176470CT.gov Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | — | Active Not Recruiting | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07376317CT.gov Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) | — | Active Not Recruiting | — | — | — |
NCT04697576CT.gov Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma | — | Recruiting | — | — | — |
NCT04708418CT.gov A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma | — | Active Not Recruiting | — | — | — |
NCT05050006CT.gov ITIL-168 in Advanced Melanoma | — | Terminated | — | — | — |
NCT04830124CT.gov Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6 | — | Terminated | — | — | — |
NCT05086692CT.gov A Beta-only IL-2 ImmunoTherapY Study | — | Recruiting | — | — | — |
NCT04995094CT.gov Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma | — | Withdrawn | — | — | — |
NCT04990479CT.gov Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma | — | Terminated | — | — | — |
NCT04902040CT.gov Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | — | Terminated | — | — | — |
NCT04855435CT.gov Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | — | Recruiting | — | — | — |
NCT04462406CT.gov Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | — | Active Not Recruiting | — | — | — |
NCT04301011CT.gov Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | — | Terminated | — | — | — |
NCT04007744CT.gov Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03842943CT.gov Neoadjuvant Combination Immunotherapy for Stage III Melanoma | — | Recruiting | — | — | — |
NCT03873818CT.gov Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | — | Completed | — | — | — |
NCT03698019CT.gov A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma | — | Active Not Recruiting | — | — | — |
NCT03589339CT.gov NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | — | Active Not Recruiting | — | — | — |
NCT03595683CT.gov Pembrolizumab and EDP1503 in Advanced Melanoma | — | Terminated | — | — | — |
NCT03620019CT.gov Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | — | Completed | — | — | — |
NCT03633110CT.gov Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | — | Completed | — | — | — |
NCT03611868CT.gov A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03590054CT.gov Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
NCT02965716CT.gov Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT03396952CT.gov Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma | — | Completed | — | — | — |
NCT03384836CT.gov Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery | — | Suspended | — | — | — |
NCT03276832CT.gov Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma | — | Completed | — | — | — |
NCT03325101CT.gov Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | — | Terminated | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03050060CT.gov Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | — | Terminated | — | — | — |
NCT02748564CT.gov Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | — | Terminated | — | — | — |
NCT03021460CT.gov Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02812693CT.gov Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | — | Withdrawn | — | — | — |
NCT02858869CT.gov Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | — | Completed | — | — | — |
NCT02595866CT.gov Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | — | Completed | — | — | — |
NCT02506153CT.gov Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02500576CT.gov Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02298959CT.gov Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | — | Active Not Recruiting | — | — | — |
NCT03311542CT.gov Expanded Access for Pembrolizumab (MK-3475) | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cutaneous Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Melanoma Institute Australia | P3 | BB · 65 |
| Alpha-Interferon | MIPO Clinic | P3 | BBB |
| Tyrosinase Peptide | University of Southern California | P3 | BBB |
| Cis-Diamminedichloroplatinum Ii | MIPO Clinic | P3 | BBB |
| TIL | City of Hope Medical Center | P2 | BBB |
| Dacarbazine | Linnaeus Therapeutics, Inc. | P3 | BBB |
| Multi-Epitope Melanoma Peptide Vaccine | Craig L Slingluff, Jr | P2 | BB |
| Nivestim | Vastra Gotaland Region | P3 | BB |
| Cediranib | Jonsson Comprehensive Cancer Center | P3 | BB |
+42 more in the Cutaneous Melanoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Cutaneous Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-cutaneous-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →